Insider Buys: Enxing Seng Stacy Purchases LivaNova Shares
Enxing Seng Stacy acquired 2,383 shares of LivaNova PLC, reflecting insider confidence.
Key Points
- Enxing Seng Stacy bought 2,383 shares of LivaNova PLC (LIVN) on June 15, 2026, with shares trading at $79.48.
- LivaNova has a market cap of $4.31 billion, a P/E ratio of 40.05, and a forward P/E of 16.95.
- Peers like FMR LLC increased holdings by 2,620,791 shares, while others like Millennium Management reduced theirs.
On June 15, 2026, Enxing Seng Stacy made an insider purchase of 2,383 shares of LivaNova PLC, traded under the ticker LIVN on the NasdaqGS. The shares were acquired without a planned purchase agreement, demonstrating personal confidence in the company's prospects as the stock traded at $79.48.
Insider Buying and Selling at LivaNova PLC
Several insiders were active at LivaNova on June 15, 2026. Alongside Enxing Seng Stacy, Ahmet Tezel, the Chief Innovation Officer, bought 2,965 shares. Francesco Bianchi purchased 2,383 shares, while Todd Schermerhorn acquired 4,042 shares. Donald Zurbay, however, sold 308 shares at an average price of $79.70.
Other Institutional Activity in LivaNova
Institutional activity in LivaNova showed varied strategies. FMR LLC increased its holdings significantly by 2,620,791 shares, bringing its total to 2,666,674 shares valued at approximately $169.49 million. AQR Capital Management LLC also raised its stake, adding 339,230 shares to reach a total of 2,494,372 shares worth about $154.38 million. Conversely, Millennium Management LLC cut its position by 1,045,411 shares, leaving it with 2,438,671 shares valued at $155.00 million. BlackRock, Inc. and Artisan Partners Limited Partnership also reduced their positions.
LivaNova PLC Stock Snapshot
LivaNova PLC currently trades near $79.48, with a market capitalization of $4.31 billion. The company has a P/E ratio of 40.05 and a forward P/E of 16.95, indicating expectations of earnings growth. The stock's beta is 0.884, suggesting it is less volatile than the market. Over the past 52 weeks, the stock has ranged from $41.02 to $80.96, with a 50-day moving average of $69.67 and a 200-day moving average of $62.48.
Recent Earnings
In its recent earnings report, LivaNova posted revenue of approximately $1.43 billion, marking a growth of 14.3%. The company achieved a net margin of 7.48% and a return on equity of 9.54%. Its next earnings date is set for August 5, 2026.
Analysts Set New Price Targets
Analysts have varied views on LivaNova's stock. On May 7, 2026, Barclays maintained a 'hold' rating with a $76.00 price target, while Mizuho and Baird reiterated their 'buy' ratings with targets of $90.00 and $76.00, respectively. The consensus recommendation is a 'buy', with a mean target price of $80.60 based on 10 analyst opinions.
About LivaNova PLC
LivaNova PLC is a medical technology company based in London, United Kingdom. It operates in the healthcare sector, specifically within the medical devices industry. The company designs and manufactures products for cardiopulmonary and neuromodulation therapies. Under the leadership of CEO Vladimir A. Makatsaria, LivaNova employs about 3,300 people and serves healthcare professionals and hospitals worldwide.
Bottom Line
Enxing Seng Stacy's purchase of LivaNova shares is a positive signal of insider confidence. LivaNova's financial metrics, including a solid revenue growth and a forward-looking P/E ratio, suggest potential growth. Institutional investors have shown mixed actions, with some increasing their stakes while others have reduced theirs. The recent analyst ratings highlight a general positive sentiment towards the stock, with several maintaining a 'buy' recommendation.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.